WO2016133824A1 - Compositions cosmétiques et topiques comprenant du cannabigérol - Google Patents

Compositions cosmétiques et topiques comprenant du cannabigérol Download PDF

Info

Publication number
WO2016133824A1
WO2016133824A1 PCT/US2016/017814 US2016017814W WO2016133824A1 WO 2016133824 A1 WO2016133824 A1 WO 2016133824A1 US 2016017814 W US2016017814 W US 2016017814W WO 2016133824 A1 WO2016133824 A1 WO 2016133824A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
extract
cream
topical composition
composition
Prior art date
Application number
PCT/US2016/017814
Other languages
English (en)
Inventor
Lekhram CHANGOER
George ANASTASSOV
Original Assignee
Axim Biotechnologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axim Biotechnologies, Inc. filed Critical Axim Biotechnologies, Inc.
Priority to DK16752852.0T priority Critical patent/DK3258942T3/da
Priority to EP16752852.0A priority patent/EP3258942B1/fr
Priority to ES16752852T priority patent/ES2860452T3/es
Publication of WO2016133824A1 publication Critical patent/WO2016133824A1/fr
Priority to HK18107903.1A priority patent/HK1248526A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations

Definitions

  • This invention relates to topical cosmetics and dermatological compositions and the topical application of such compositions to the skin for the prevention and/or treatment of damage to the skin.
  • the topical compositions comprise cannabigerol, a non-psychoactive phytocannabinoid.
  • the topical composition is anti-aging day cream, anti-aging night cream, eye cream, hand and nail cream, lip balm, acne cream and tonic, face wash, shampoo and conditioner, body wash, deodorant, or anti-diaper rash cream.
  • the cannabis plant has many naturally occurring substances that are of great interest in the fields of science and medicine.
  • Isolated compounds from the cannabis plant include
  • THC cannabidiol
  • CBD cannabichromene
  • CBC cannabigerol
  • CBD cannabinol
  • CBDV cannabidivarin
  • THC (-)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl-
  • CBD's IUPAC nomenclature is 2-((lS,6S)-3- methyl-6-(prop-l-en-2-yl)cyclo-hex-2-enyl)-5-pentylbenzene-l,3-diol).
  • CBC has the IUPAC nomenclature of 2-methyl-2-(4-methylpent-3-enyl)-7pentyl-5-chromenol.
  • CBG has the IUPAC nomenclature of 2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-pentyl-benzene-l,3-diol. These are among the most prominent compounds in the family of compounds extracted from the cannabis plant referred to as cannabinoids.
  • CBG cannabigerol
  • CBG has been shown to relieve intraocular pressure, which may help in the treatment of glaucoma. It can also be used to treat inflammatory bowel disease. CBG also inhibits the uptake of ⁇ -aminobutyric acid (GABA) in the brain, which in turn helps decrease anxiety. Research on rats has shown that CBG has an anti-nausea and anti-emetic effect, although human testing has yet to be carried out. One study even suggests that CBG inhibits the growth of color cancer cells. Another study found that CBG could potentially be helpful to treat many central nervous system disorders such as epilepsy.
  • GABA ⁇ -aminobutyric acid
  • Cannabinoids can be isolated by extraction or cold pressing from cannabis plants. Plants in the cannabis genus include Cannabis sativa, Cannabis ruderalis, and Cannabis indica. These plants are the natural sources of cannabinoids. Cannabinoids are also available in synthetic forms. Methods to synthesize cannabinoids in lab settings were discovered and are still currently practiced. Synthetic cannabinoids are more targeted, in that the synthetic compound usually comes isolated without other cannabinoids mixed in.
  • Nabilone (racemic(6aR,10aR)-l-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)- 7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one), a synthetic cannabinoid, is believed to have fewer undesired side effects than THC. Nabilone mimics the chemical compound structure of THC. THC also exists in synthetic form under the name Dronabinol ((-)-(6aR,10aR)-6,6,9- trimythel-3-pentyl-6a,7,8, 10a-tetrahydro-6H-benzo[c]chromen- l-ol)).
  • nabilone for treatment of chemotherapy-induced nausea and vomiting. In the United States, nabilone is marketed under the name Cesamet ® .
  • Cosmetics are body-care substances used to enhance the human body's appearance or odor. Cosmetics are used to cleanse, beautify, promote attractiveness, and alter appearance without affecting the body's structure or function.
  • cosmetics applied to the skin (face and body), cosmetics applied to the lips, cleansing cosmetics (soap, shampoo, and conditioner), cosmetics applied to change odor (perfume, body mist, deodorant), and cosmetics applied to the eyes (mascara, eyebrow pencil).
  • Polyunsaturated fatty acids are essential to skin health. Metabolism of linoleic acid and alpha-linoleic acid is limited in the skin. Topical and oral supplementations of essential fatty acids are effective means to supply these essential fatty acids to the skin. Some anti-aging cosmetic products do not include these important polyunsaturated fatty acids.
  • Essential fatty acids found in hemp oil act as moisturizers to trap moisture on the skin. Moreover, the fatty acids ratio in hemp oil closely matches the human skin composition and body, which is 3: 1 ratio of omega-6 to omega-3 essential fatty acids. EFAs are proven to play a preventive role in skin aging and a healthy moisture balance for the skin.
  • Omega fatty acids are a group of unsaturated fatty acids considered to be important to physiological development in mammals.
  • omega-3 fatty acids are considered to be vital for normal metabolism.
  • These fatty acids receive their names based on the location of the first double bond from the tail end (omega end) of the carbon chain.
  • Omega-3 fatty acids are a group of three (3) fatty acids called a-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). Mammals have limited ability to synthesize omega-3 fatty acids. Given their importance in metabolism, mammals must consume omega-3 fatty acids to ensure normal metabolism.
  • ALA a-linolenic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • Omega-6 fatty acids are a family of unsaturated fatty acids that have in common a carbon-carbon double bond in the n-6 position. Omega-6 fatty acids are considered to be important to a mammal's diet. The relative ratio of omega-6 to omega-3 fatty acids in Western diet is about 10: 1 and up to 30: 1. An excessive ratio of omega-6 to omega-3 fatty acids may interfere with omega-3 activity, storage, and conversion to eicosanoid precursors.
  • Terpenes refer to a large class of organic compounds produced by a variety of plants, particularly conifers. It is believed that they protect the plants that produce them by deterring herbivores and actually attracting predators and parasites of herbivores. Terpenes are the major ingredient in resin and form some of the major biosynthetic building blocks within nearly every living creature. Terpenes are the primary constituents of the essential oils of many plants. These essential oils are widely used as natural flavor additives for food, as fragrances in perfumes, and in medicine and alternative medicines in the form of aromatherapy. They are released by trees more actively in warmer weather and act as a natural form of cloud seeding, helping to regulate the temperature of the forest. Terpenes form the aroma and flavor in hops, which are highly desirable in some beers.
  • Terpin hydrate is a derivative of turpentine, and as an expectorant or humectant it is commonly used in the treatment of chronic or acute bronchitis and related conditions.
  • Cosmetics applied to the skin usually have antimicrobial, anti-oxidant, anti-aging, and wound healing properties.
  • Various substances are added to cosmetics to achieve these effects, and continuous efforts are still made to identify substances with these properties to be used in cosmetics.
  • the present invention relates to topical compositions comprising hemp oil or cannabis oil with naturally occurring cannabigerol at 3% to 24% by weight of the oil and cannabidiol at 1% to 10% by weight, and the oil comprises 0.2% to 10% by weight of the topical leave-on composition.
  • the concentrations of CBG hemp oil or cannabis oil are at 0.05% to 1.0% by weight of the topical rinse-off composition.
  • the topical composition is formulated to be anti-aging day cream, anti-aging night cream, eye cream, hand and nail cream, lip balm, acne cream and tonic, diaper rash cream, shampoo or conditioner, deodorant spray, face wash, or body wash.
  • the present invention also relates to methods to make the topical composition, and methods to use the topical composition for anti-aging, nourishing, cleansing, and acne treatment purposes.
  • CBD Cannabidiol
  • CBDV Cannabidivarin
  • CBG Cannabigerol
  • CBN Cannabinol
  • GAB A ⁇ -aminobutyric acid
  • THC Tetrahydrocannabinol
  • cannabinoid used in this description, claims, and other conjugations is used to mean any compound that interacts with a cannabinoid receptor and other cannabinoid mimetics, including, but not limited to, certain tetrahydropyran analogs ⁇ -tetrahydrocannabinol, A 8 -tetrahydrocannabinol, 6,6,9-trimythel-3-pentyl-6H-dibenzo[b,d]pyran-l-ol, 3-(l,l- dimethylheptyl)-6,6a7,8,10,10a-hexahydro-l-lhydroxy-6,6-dimythel-9H-dibezo[b,d]pyran-9- ol,(-)-(3S,4S)-7-hydroxy-delta-6-tetrahydrocannabinol-l,l-dimethylheptyl, (+)-(3S,4S)-7- hydroxy
  • cannabidiol refers to cannabidiol and cannabidiol derivatives.
  • cannabidiol is obtained from industrial hemp extract with a trace amount of THC or from cannabis extract using high-CBD cannabis cultivars.
  • annabigerol refers to cannabigerol and cannabigerol derivatives.
  • cannabigerol is industrial hemp extract with a trace amount of THC or from cannabis extract.
  • annabinol refers to cannabinol and cannabinol derivatives. As used in this application, cannabinol is obtained from cannabis extract or from industrial hemp extract.
  • annabinol refers to cannabinol and cannabinol derivatives. As used in this application, cannabinol is obtained from cannabis extract or from industrial hemp extract.
  • Cannabinoids derived from natural sources usually come in oily form, known as cannabis oil, hashish oil, or hemp oil, depending on its origin, and is extract of the plant Cannabis sativa L.. Cannabis sativa L.'s seed oil with naturally occurring cannabinoid content may also be used.
  • the oil has a liquid to paste-like profile at room temperature, and is hydrophobic.
  • Cannabis sativa L.'s seed oil or plant oil high in naturally occurring CBG may be used.
  • the topical dermatological compositions in these embodiments comprise Cannabis sativa L.'s oil with naturally occurring CBG.
  • CBG may be present in this oil at 3% to 24% by weight, even though higher weight percentage is contemplated.
  • Other naturally occurring cannabinoids may also be present, such as CBD at 3% to 10% by weight, and THC, CBC, CBN, or CBDV at lower weight percentage.
  • Cannabis oil or hemp oil with high naturally occurring CBG has anti-bacterial, anti- aging, neuro-protective, moisturizing, and anti-oxidant properties.
  • CBG oil may prevent and treat damage on skin, and may moisturize the skin to give a youthful appearance.
  • Anti-bacterial properties may help minimize the chance of acne development, as well as treating on-going acne on the dermis.
  • Topical dermal compositions used on the skin during daylight should have ultraviolet (UV) ray protection properties to protect the dermis from sun damage.
  • UV ultraviolet
  • CBG has neuro-protective properties as well as anti-oxidant properties, which may be useful is prevention of photodamage of the skin from UV rays exposures.
  • Terpenes in hemp oil or cannabis oil may provide anti-microbial properties, which may be desirable in cosmetics used for cleansing and/or in cosmetics applied to the skin. Terpenes may also add to the flavor of the cosmetics as a whole.
  • the topical composition may contain cannabis oil or hemp oil with naturally occurring CBG and CBD at about 0.2% to 10% by weight of the total composition, more preferably at about 2% to about 5% by weight of the total composition, for stay-on formulations.
  • Stay-on formulations are topical compositions applied to the skin and are not rinsed-off within a few minutes.
  • the topical composition may contain cannabis oil or hemp oil with naturally occurring CBG and CBD at about 0.05% to 1% by weight of the total composition.
  • Rinse-off formulations are topical compositions that may be rinsed off with water within a few minutes after application.
  • the topical composition may comprise other ingredients.
  • Anti-glycation agents may be added to this topical composition.
  • Anti-glycation agents are compounds for preventing and/or reducing the glycation of skin protein, such as a dermal protein like collagen.
  • the anti-glycation agent may inhibit the formation of advanced glycation end products.
  • Anti-glycation agents may be present in the topical composition at 0.1% to 5% by weight of the total composition.
  • anti-glycation agents may be extracts of Vaccinium angustifolium (blueberry), ergothioneine and its derivatives, hydroxystilbenes and their derivatives, benfotimaine, pyrisoxamine, G-rutin, pyridoxal phosphate, green tea extract, curcumin extract, Lupius albas seed oil, or Kigelia africana extract. Other anti-glycation agents may also be used.
  • Anti-inflammatory agents may be added to the topical composition to prevent and treat skin inflammation. Free radicals produced in aging skin may also induce inflammation of the skin and reduce skin immunity. Anti-inflammatory agents in topical compositions may work to reduce inflammation and increase skin health.
  • Useful anti-inflammatory agents may be NSAIDS and COX-2 inhibitors, such as curcumin extract, evodia extract, Camellia sinesis extract, cocoa seed butter, citric acid, salicylic acid, tocopherol, loganin, palmatine, Vitis vinifera extract, among other anti-inflammatory ingredients.
  • Anti-inflammatory agents may be present in the topical composition at 0.5% to 20% by weight.
  • ROS Reactive oxygen species
  • Living tissues have a control mechanism to keep ROS in balance.
  • Endogenous antioxidants defend the human body against ROS. When insufficient endogenous antioxidants are present, antioxidant supplements may work to inhibit the production of ROS by direct scavenging.
  • Antioxidants may also decrease the amount of oxidants in and around our cells, prevent ROS from reaching their biological targets, limit the propagation of oxidants, thwart oxidative stress, and ultimately prevent the aging process.
  • Anti-oxidants may be useful in cosmetic formulations to ease oxidative stress and prevent collagen degradation in the skin.
  • Suitable anti-oxidants for this topical formulation may be Vitis vinifera extract, tocopherol and tocopherol derivatives, certain lycopenes such as ⁇ - carotene, certain anthocyans (blueberry extract, basil grape extract), certain catechins (green tea extract, grape seed extract, litchi extract), certain quercetins (blueberry extract, grape seed extract, apple extract), certain genistein extract (gingoko biloba extract, soja extract), acetyl hexapeptide- 3, Silybum marianum fruit extract, or silymarin (milk thistle).
  • Anti-oxidants may be incorporated into the topical formulation at 0.1% to 30% by weight of the total composition.
  • Anti-microbial ingredients protect against the growth of microorganisms in personal care products. Anti-microbial agents may also kill microorganisms present in the cosmetic product from the manufacturing process. Anti-microbial agents may be present in these embodiments to safeguard against microbial overgrowth, which may compromise the composition's quality as a whole.
  • Suitable anti-microbial agents may be imidazolidinyl urea, sodium chloride, or certain extracts having anti-microbial activities such as Matricaria chamomilla extract, Aloe vera extract, Calendula officinalis extract, Kigelia africana extract, Lavandulla officinallis essential oil, Melaleuca alternifolia essential oil, or Cinnamomum zeylanicum essential oil.
  • Anti-microbial agents may be present in the topical composition at 0.5% to 15% by weight of the total composition.
  • UV exposure may lead to multiple cellular damage by generating 0 2 , H2O2, [-OH] and other reactive oxygen species.
  • the presence of oxidative groups may lead to skin aging, actinic damage, collagen and elastin degradation.
  • UVB rays (290 - 320 nm) are absorbed by epidermal chromophores such as melanin and urocanic acid and lead to direct molecular damage.
  • UVA rays (320 - 400 nm) penetrate more deeply in the dermis, increase the production of ROS, and contribute to long-term actinic damage. UV ray damages may be mitigated with the use of certain agents that prevent and/or disrupt the destructive reactions caused by UV rays.
  • Suitable UV ray filter for this topical composition may be butylene glycol dicaprylyate or dicaprate, ethylhexyl methoxycinnamate, bis-ethylhexylloxyphenol methoxyphenyl triazine, camphor benzalkonium methosulfate, diethylhexyl butamido triazone, bisdisulizole disodium, drometrizole trisiloxane, ethylhexyl triazone, methyl anthranilate, 4- methylbenzylidene camphor, methylene bis-benzotriazolyl tetramethylbutyl phenol, octocrylene, butyl methoxydibenzoylmethane, phenylbenzimidazole sulfonic acid, polyacrylamidomethyl benzylidene camphor, or terephthalylidene dicamphor sulfonic acid.
  • UV ray filters may be added into the topical composition in embodiments used during the day, when skin exposure to sunlight is expected. UV ray filters may not be necessary for the topical compositions used during the night. UV ray filter agents may be present in the topical composition at 2% to 30% by weight of the total composition.
  • the topical composition may further comprise multiple skin conditioning agents.
  • Skin conditioning agents may work to increase moisture retention of the upper dermis layer, and thus give the skin an appearance of suppleness.
  • Certain skin conditioning agents may work to reduce flaky appearance and attract moisture from the environment, like a humectant.
  • Suitable skin conditioning agents may be butyrospermum parkii (shea butter), pentylene glycol, acetyl hexapeptide-3, lipobelle soyaglycone, xylitylglucoside, anhydroxyxylitol, xylitol, ethylhexylglycerin, squalene, Triticum vulgar e germ oil unsaponifiables, ceramide-3, ethylhexyl stearate, biosaccharide gum-1, paraffinum liquidum, isopropyl palminate, glycerin stearate, D-panthenol, lactic acid, tocopherol and tocopherol derivatives, cetearyl alcohol, dicaprylyl carbonate, butylene alcohol, butylene glycol, and carnosine, butylene glycol cocoate, propylheptyl caprylate, glycine soja sterols (shea butter
  • the topical composition may be a rash cream to treat diaper rash and other common rashes.
  • the topical composition may further comprise a soothing agent such as oxidized corn oil to provide a soothing feeling to the skin.
  • agents with keratolytic effect may be added into the topical composition. Hydrolyzed keratin and/or allantoin with keratolytic effect may be used in these embodiments. Keratolytic agents may be incorporated into this composition at 0.1% to 5% by weight of the total composition.
  • Additional preservatives may be added into the topical composition to extend shelf life and prevent microbial growth.
  • Suitable preservatives may be pentylene glycol, phenoxyethanol, methyl and propylparaben, or ethylhexyl glycerin, or benzyl alcohol.
  • Other preservatives suitable for cosmetic use may also be used.
  • Preservatives may be present in the topical composition at 0.5% to 10% by weight of the total composition.
  • the topical formulation may comprise water, preferably de-ionized water, as the base, and bulking agent in this formulation. Water may comprise about 40% to about 80% by weight of the topical composition. However, in an embodiment wherein the topical composition is a lip balm, the composition comprises no water.
  • Viscosity controlling agents and emulsifiers may be necessary to bind water-phase ingredients and oil-phase ingredients.
  • Suitable emulsifiers for these embodiments may be hydrogenated lecithin, glycerin, sodium gluconate, acrylates, C 10-30 alkyl acrylate crosspolymer, sodium carboxymethyl betaglucan, hydrogenated castor oil, polyglyceryl-3 methylglucose distearate, cetearyl alcohol, behenyl alcohol, butylene glycol, propylene glycol, xanthan gum, potassium cetyl phosphate, polyglyceryl-6 distearate jojoba esters, polyglyceryl-3 beewax, cetyl alcohol, PEG-800, laureth-7, C13-14 isoparrafin, polyisobutene, sodium carboxymethyl betaglucan, PEG-200 hydrogenated glyceryl palmate, cellulose gum, PEG-7 glyceryl cocoate, or aluminum starch
  • the topical composition may further comprise a foaming agent as needed.
  • Foaming agents may be quillaia saponaria extract or disodium EDTA (disodium ethylenediaminetetraacetic acid).
  • Fragrance agents in these embodiments may be added to increase the aesthetic appeal of the topical composition.
  • Fragrances may be propylparaben, hydrogenated castor oil, cinnamal, eugenol, coumarin, linalool, a-isomethyl ionone, hydroxyisohexyl 3-cyclohexene carboxaldehyde, butylphenyl methylpropional, or natural fragrance essential oils.
  • the topical composition according to the above embodiments may be formulated to be an anti-aging day cream, anti-aging night cream, hand and nail cream, acne treatment cream or tonic, anti-diaper rash cream, shampoo (regular and anti-dandruff), conditioner, face wash, and body wash.
  • the topical composition is a lip balm.
  • the topical composition may comprise, apart from CBG hemp oil or CBG cannabis oil at about 1% to 3% by weight of the topical composition, cosmetically suitable waxes, cosmetic oils or butter, flavor, and moisturizing agents.
  • CBG hemp oil or CBG cannabis oil as used in these embodiments may have about 3% to 24% CBG, and 1% to 10% CBD by weight, with other naturally occurring cannabinoids at lower weight percentage.
  • Suitable waxes for use in this embodiment may be bee wax, lanolin, candelilla, soy, or camauba wax.
  • Other skin conditioning agents may be added to give the composition a softer profile.
  • Suitable skin conditioning agents may be cocoa butter, Ricinus communis (castor) seed oil, olive oil, coconut oil, and avocado oil. Other suitable skin conditioning agents may also be used.
  • Flavoring oils such as apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, kiwi, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, honey, or any suitable flavor, may be added into the topical composition according to this embodiment.
  • flavoring oils such as apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry
  • the topical composition may be a shampoo, conditioner, a face wash, or body wash
  • the topical composition may contain, apart from CBG hemp oil or CBG cannabis oil, other ingredients common in shampoo, conditioner, face wash, or body wash.
  • the concentrations of CBG hemp oil or CBG cannabis oil in these products may be at 0.05% to 1% by weight of the topical rinse-off composition.
  • Suitable surfactants, cleansing agents, additives, antimicrobials, and thickeners in these embodiments may be ammonium chloride, ammonium lauryl sulfate, sodium laureth sulfate, sodium lauryl sulfate, piroctone olamine, sodium lauroamphoacetate, polysorbate 20, polysorbate 80, PEG-150, citric acid, quaternium-15, polyquaternium-10, coco-glucoside, cocamide MEA, methylisothiazolinone, or di-PGG-2 myreth-10 adipate.
  • Piroctone olamine may be used as an antimicrobial agent in shampoo embodiments for anti-dandruff purposes.
  • the topical composition may be a conditioner.
  • the conditioner may comprise, in addition to CBD hemp oil or CBG cannabis oil, certain humectants; certain reconstructors such as hydrolyzed protein, glossers such as silicones; thermal protectors; certain lubricants such as fatty alcohols, panthenol, or dimethicone; certain sequestrants, such as sodium gluconate, potassium gluconate, or calcium disodium ethylene diamine tetra-acetate; antistatic agents; or preservatives.
  • the topical composition may be a deodorant spray.
  • the deodorant spray according to these embodiments may comprise CBG hemp oil or CBG cannabis oil at 0.1% to 1.5% by weight of the deodorant spray as a whole.
  • CBG hemp oil or CBG cannabis oil as used in these embodiments may have about 3% to 24% CBG, and 1% to 10% CBD by weight, with other naturally occurring cannabinoids at lower weight percentage.
  • the deodorant spray may further comprise alcohol, such as ethanol and isopropyl alcohol as the main carrier.
  • Suitable emulsifiers and humectants may be added, such as glycerin, polysorbate 20, methylcyclodextrin, or ethylhexyl glycerin. Other suitable emulsifiers may also be used. Fragrance in the form of natural essential oils may be added to give a pleasant scent.
  • Flavoring oils such as apple, cherry, green tea, cinnamon, clove, black tea, plum, mango, date, watermelon, coconut, pear, jasmine, peach, fennel, fragrant melon, lychee, mint, chocolate, coffee, cream, banana, almond, grape, strawberry, blueberry, blackberry, pine, kiwi, sapote, taro, lotus, pineapple, orange, lemon, melon, peach, licorice, vanilla, rose, osmanthus, kiwi, ginseng, spearmint, citrus, cucumber, honeydew, walnut, almond, honey, or any suitable flavor, may be added into the deodorant spray as fragrance according to these embodiments.
  • ingredients may be obtained according to the embodiments above.
  • Water phase ingredients may be combined and mixed.
  • Oily phase ingredients may be combined and mixed with heat application at about 50 °C to about 70 °C to reduce viscosity and facilitate mixing.
  • Water phase and oil phase may be combined under continuous mixing and heating.
  • the water phase comprises of de-ionized water, bulking agents, cosmetic fillers, emulsifiers, preservatives, and anti-caking agents. Ingredients for the water phase may be combined and mixed. Water phase ingredients may be separated into different sequences as needed.
  • the oily phase may comprise hemp oil, tocopherol, lipobelle soyaglycone, fragrance, essential oils, and other oily ingredients. Ingredients for the oily phase may be combined and mixed while heated. Other ingredients may be added in sufficient quantities, such as sodium hydroxide for pH balancing purposes.
  • ingredients may be obtained according to the above embodiments.
  • the lip balm composition may be applied to lips.
  • ingredients may be obtained according to the description above.
  • a base comprising of water and alcohols may be pre- mixed in a container.
  • Emulsifiers and humectants may be mixed with CBG hemp oil or CBG cannabis oil; then added into the base. Fragrance may be added as needed to the composition.
  • Anti-aging creams according to embodiments may be applied at least once daily to human skin to reduce signs of aging, including sagging skin, discoloration, dryness, and crow's feet.
  • Hand and nail cream may be applied at least once daily to nourish and moisturize the skin.
  • Acne cream according to the present invention may be applied at least once daily to prevent and treat acne.
  • Lip balm according to these embodiments may be applied as needed to the lips to moisturize and preserve lips' health.
  • Shampoo, conditioner, face wash, and body wash according to these embodiments may be applied to the hair or skin with water to wash, nourish, and moisturize the hair and the skin.
  • Shampoo, conditioner, face wash, and body wash may be applied daily, or as needed.
  • Deodorant spray may be applied to the skin twice daily or as needed.
  • Sequence #2 In another beaker, combine Sequence #2, heat to 40 °C and mix. Pour Sequence #2 into Sequence #1. 3. Add Sequence #3 into the main beaker and mix. Pour the mix into cylindrical molds. Cool the mixture down to room temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
  • Gerontology & Geriatric Medicine (AREA)

Abstract

La présente invention concerne différents produits cosmétiques et formulations topiques comprenant du cannabigérol, un cannabinoïde non psychoactif. La formulation peut être une crème antivieillissement pour application le jour ou la nuit, une crème pour les mains et les ongles, une crème pour les yeux, une crème de traitement de l'acné ou une crème tonifiante, une crème anti-érythème fessier du nourrisson, un shampooing, un conditionneur, un nettoyant pour le corps, un nettoyant pour le visage, un aérosol déodorant ou une formulation de baume pour les lèvres. Ces formulations topiques et cosmétiques ont des propriétés d'accélération de la cicatrisation des plaies, de raffermissement de la peau, antbactériennes, antipelliculaires, de lissage de la peau et de protection contre les rayons UV.
PCT/US2016/017814 2015-02-16 2016-02-12 Compositions cosmétiques et topiques comprenant du cannabigérol WO2016133824A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DK16752852.0T DK3258942T3 (da) 2015-02-16 2016-02-12 Kosmetiske og topiske sammensætninger omfattende cannabigerol og cannabidiol
EP16752852.0A EP3258942B1 (fr) 2015-02-16 2016-02-12 Compositions cosmétiques et topiques comprenant du cannabigérol et du cannabidiol
ES16752852T ES2860452T3 (es) 2015-02-16 2016-02-12 Composiciones cosméticas y tópicas que comprenden cannabigerol y cannabidiol
HK18107903.1A HK1248526A1 (zh) 2015-02-16 2018-06-20 包含大麻萜酚的化妝品和局部施用組合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562116905P 2015-02-16 2015-02-16
US62/116,905 2015-02-16

Publications (1)

Publication Number Publication Date
WO2016133824A1 true WO2016133824A1 (fr) 2016-08-25

Family

ID=56620605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/017814 WO2016133824A1 (fr) 2015-02-16 2016-02-12 Compositions cosmétiques et topiques comprenant du cannabigérol

Country Status (6)

Country Link
US (2) US20160235661A1 (fr)
EP (1) EP3258942B1 (fr)
DK (1) DK3258942T3 (fr)
ES (1) ES2860452T3 (fr)
HK (1) HK1248526A1 (fr)
WO (1) WO2016133824A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107789255A (zh) * 2017-11-30 2018-03-13 安徽扬子生物科技有限公司 一种茉莉花抗菌沐浴露配制方法
GB2554966A (en) * 2016-05-23 2018-04-18 Henkel Ag & Co Kgaa Deodorizing combination of active ingredients
WO2019140357A1 (fr) * 2018-01-13 2019-07-18 Truetiva Inc. Compositions anti-âge et d'éclaircissement du teint de la peau et méthodes associées
WO2019144189A1 (fr) * 2018-01-24 2019-08-01 Botanix Pharmaceuticals Ltd Régime de dosage de cannabinoïde pour l'acné
WO2020000024A1 (fr) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Traitement antibactérien utilisant des combinaisons de cannabinoïdes
US10857107B2 (en) 2017-02-01 2020-12-08 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
WO2020252522A1 (fr) * 2019-06-18 2020-12-24 Botanix Pharmaceuticals Limited Régime posologique antibactérien utilisant des cannabinoïdes
WO2021092340A1 (fr) * 2019-11-07 2021-05-14 Amyris, Inc. Compositions et procédés d'administration de cannabinoïdes à la peau
WO2021116808A1 (fr) * 2019-12-10 2021-06-17 Avicanna Inc. Composition topique de soin de la peau et méthodes de traitement de l'eczéma
US11213467B2 (en) 2019-11-07 2022-01-04 Amyris, Inc. Compositions and methods for delivering cannabinoids to skin
WO2022150761A1 (fr) * 2021-01-11 2022-07-14 Amyris, Inc. Compositions cosmétiques et ses procédés d'utilisation
WO2023012803A1 (fr) * 2021-08-05 2023-02-09 Technion Research & Development Foundation Limited Cannabinoïdes et leurs utilisations dans le traitement d'une maladie
EP4268799A1 (fr) * 2022-04-01 2023-11-01 TF Holdings LLC Composition de traitement de la peau contenant des cannabinoïdes
US11980592B2 (en) 2016-10-11 2024-05-14 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108451799A (zh) * 2016-12-09 2018-08-28 汉义生物科技（北京）有限公司 一种洗手液及其制备方法
DE202016107001U1 (de) * 2016-12-15 2018-03-26 Schwan-Stabilo Cosmetics Gmbh & Co. Kg Kosmetische Zubereitung in Gelform
MX2019013262A (es) * 2017-05-07 2020-01-13 Locus Ip Co Llc Composiciones cosmeticas para la salud de la piel y metodos de uso de los mismos.
US10624939B2 (en) * 2017-05-23 2020-04-21 Luke Klele Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression
US10905647B2 (en) 2017-06-30 2021-02-02 The Procter & Gamble Company Antiperspirant and deodorant compositions
US10543164B2 (en) 2017-06-30 2020-01-28 The Procter & Gamble Company Deodorant compositions
EP3644951A1 (fr) 2017-06-30 2020-05-06 The Procter and Gamble Company Compositions de soins capillaires comprenant un matériau de type 2-pyridinol-n-oxyde et un chélateur du fer
CA3066177C (fr) 2017-06-30 2023-06-06 The Procter & Gamble Company Compositions deodorantes et antitranspirantes
KR20200024908A (ko) * 2017-07-06 2020-03-09 디에스엠 아이피 어셋츠 비.브이. 국소 조성물
CN109248107A (zh) * 2017-07-12 2019-01-22 国农兴悦(北京)生态科技有限公司 护肤油及其制备方法
US11484510B2 (en) 2017-08-28 2022-11-01 Apirx Pharmaceutical Usa, Llc Method to treat vitiligo
US20190060250A1 (en) * 2017-08-28 2019-02-28 Axim Biotechnologies, Inc. Method to treat psoriasis
US10272051B2 (en) * 2017-08-28 2019-04-30 Axim Biotechnologies, Inc. Method to treat atopic dermatitis
KR102063524B1 (ko) * 2017-11-10 2020-01-08 안용훈 칸나비디올을 포함하는 화장료 조성물
WO2019094876A1 (fr) * 2017-11-13 2019-05-16 Smoky Valley Lotions & Soaps Compositions insectifuges et procédés d'utilisation
US10905730B2 (en) * 2017-11-14 2021-02-02 Agnes V. MOJSA Phytocannabinoid topical compositions for releiving pain
WO2019113497A1 (fr) * 2017-12-08 2019-06-13 Biotech Institute LLC Plants de cannabis à teneur élevée en cannabigérol, leurs procédés de production et leurs procédés d'utilisation
US20190224137A1 (en) * 2018-01-24 2019-07-25 Botanix Pharmaceuticals Ltd. Cannabinoid Dosing Regime for Acne
EP3773528B1 (fr) 2018-04-09 2024-01-10 Portland Technology Holdings LLC Extrait de chanvre pour le traitement de la douleur chez les animaux
CN108354865A (zh) * 2018-04-17 2018-08-03 五池（珠海）日化科技有限公司 一种保湿去皱抗过敏组合物及其制备方法
CN108524414A (zh) * 2018-04-20 2018-09-14 烟台汉麻生物技术有限公司 一种多功效汉麻面膜及其制备工艺
CA3107300A1 (fr) 2018-05-25 2019-11-28 Locus Ip Company, Llc Compositions therapeutiques permettant la cicatrisation amelioree de plaies et de cicatrices
WO2019234743A1 (fr) * 2018-06-06 2019-12-12 Icdpharma Ltd. Compositions synergiques anti-inflammatoires comprenant des cannabinoïdes et de la réglisse
US20200009077A1 (en) * 2018-07-03 2020-01-09 TRUETIVA, Inc. Compositions for treating dermatological diseases
CA3124321A1 (fr) * 2018-12-25 2020-07-02 Epm (Ip), Inc. Esters d'acide cannabidiolique pour compositions cosmetiques ou comestibles
JP2022539057A (ja) * 2019-06-26 2022-09-07 キャンパル アニマル セラピューティクス リミテッド Ｃｂｄ組成物
WO2021018936A1 (fr) 2019-07-29 2021-02-04 Echo Pharmaceuticals B.V. Traitement d'affections cutanées inflammatoires
WO2021050429A1 (fr) * 2019-09-10 2021-03-18 Pureform Global, Inc. Composition topique pour le traitement de la douleur
BR112022005950A2 (pt) * 2019-10-07 2022-06-28 Colgate Palmolive Co Composições e métodos de higiene pessoal
CN110711165A (zh) * 2019-11-03 2020-01-21 上海悦目化妆品有限公司 一种含袋鼠爪提取物的抗衰紧致养颜霜
MX2022007110A (es) 2019-12-16 2022-07-11 Colgate Palmolive Co Composiciones para el cuidado personal y metodos para estas.
WO2021127676A1 (fr) * 2019-12-16 2021-06-24 Colgate-Palmolive Company Compositions de soins personnels et leurs procédés
CN111956535A (zh) * 2019-12-30 2020-11-20 云南汉盟制药有限公司 一种调理剂组合物及其制备方法与应用
WO2021207182A1 (fr) * 2020-04-06 2021-10-14 Jupiter Wellness, Inc. Formulations d'écran solaire à base de cbd et leurs utilisations
US11524040B2 (en) 2020-08-24 2022-12-13 Charlotte's Web, Inc. Composition for the treatment of acne
CN112516120A (zh) * 2021-02-05 2021-03-19 云南维他源生物科技有限公司 一种具有抗衰老抗炎功效的asbd组合物及其应用
KR20220126653A (ko) * 2021-03-08 2022-09-16 주식회사 엘지생활건강 칸나비게롤을 포함하는 조성물
WO2022189945A1 (fr) * 2021-03-08 2022-09-15 Avicanna Inc. Compositions de cannabinoïde topiques et méthodes de traitement de maladies cutanées
FR3133750A1 (fr) * 2022-03-25 2023-09-29 Helioscience Nouvelles compositions associant des dérivés de chanvre et leur utilisation, notamment en cosmétique

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068347A1 (en) * 2000-01-10 2003-04-10 Werner Baschong Use of microbially encapsulated meterials in cosmetic end formulations
US20040120909A1 (en) * 2002-12-13 2004-06-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic method and composition for enhancing attractiveness
WO2006015675A1 (fr) * 2004-08-04 2006-02-16 Henkel Kommanditgesellschaft Auf Aktien Preparation cosmetique pour la peau a base de lipides polyinsatures
WO2008024408A2 (fr) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation
US20100166891A1 (en) * 2008-12-23 2010-07-01 Intendis Gmbh Composition comprising hemp oil for treating topical diseases, especially hand-foot syndrome
US20110027327A1 (en) * 2007-10-02 2011-02-03 Kuhs Gmbh Cosmetic or pharmaceutical composition for topical application
US20120237556A1 (en) * 2010-10-23 2012-09-20 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US20130142881A1 (en) * 2011-12-02 2013-06-06 The Mothervine Nutraceutical Co. Llc Lip Balm Composition
US20140030202A1 (en) * 2010-11-15 2014-01-30 L'oreal Solid cosmetic composition in compact powder form
US20140127148A1 (en) * 2011-03-25 2014-05-08 Laboratoires Urgo Fluid composition containing a sun filter, and use thereof for the treatment of scars

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19805703C2 (de) * 1998-02-06 2001-05-03 Cognis Deutschland Gmbh Haarnachbehandlungsmittel
US6361806B1 (en) * 2000-02-23 2002-03-26 Michael P. Allen Composition for and method of topical administration to effect changes in subcutaneous adipose tissue
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
DE10357046A1 (de) * 2003-12-04 2005-06-30 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen enthaltend eine Kombination aus grünem Farbstoff und antiinflammatorischem Wirkstoff
US20070280898A1 (en) * 2006-06-06 2007-12-06 P & H Enterprises Of Marco Inc. Dermatological compositions
WO2008079898A1 (fr) * 2006-12-20 2008-07-03 Pharmwest, Inc. Méthodes et formulations topiques comprenant un métal colloïdal servant à traiter ou prévenir des affections cutanées
US20080286390A1 (en) * 2007-05-16 2008-11-20 Judy Tanyi Skin care composition
KR100893106B1 (ko) * 2007-07-09 2009-04-10 정정임 발모용 조성물
US20110250227A1 (en) * 2008-08-11 2011-10-13 Hanan Elraz Composition for treatment of the skin
FR2966698B1 (fr) * 2010-10-29 2013-04-26 Dermo Cosmetique Animale Lab De Composition dermo-cosmetique anti-microbienne pour animaux
CN104066424A (zh) * 2011-09-02 2014-09-24 伯特氏农场有限责任公司 包含小果南瓜或大果南瓜提取物的个人护理组合物
US20130319889A1 (en) * 2012-05-29 2013-12-05 Surgeons Skin Recovery Stick, Llc Skin care and restoration composition and methods
US9597279B2 (en) * 2014-02-28 2017-03-21 HDDC Holdings, LLC Anti-aging dermal composition comprising herbal extracts

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068347A1 (en) * 2000-01-10 2003-04-10 Werner Baschong Use of microbially encapsulated meterials in cosmetic end formulations
US20040120909A1 (en) * 2002-12-13 2004-06-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic method and composition for enhancing attractiveness
WO2006015675A1 (fr) * 2004-08-04 2006-02-16 Henkel Kommanditgesellschaft Auf Aktien Preparation cosmetique pour la peau a base de lipides polyinsatures
WO2008024408A2 (fr) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation
US20110027327A1 (en) * 2007-10-02 2011-02-03 Kuhs Gmbh Cosmetic or pharmaceutical composition for topical application
US20100166891A1 (en) * 2008-12-23 2010-07-01 Intendis Gmbh Composition comprising hemp oil for treating topical diseases, especially hand-foot syndrome
US20120237556A1 (en) * 2010-10-23 2012-09-20 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US20140030202A1 (en) * 2010-11-15 2014-01-30 L'oreal Solid cosmetic composition in compact powder form
US20140127148A1 (en) * 2011-03-25 2014-05-08 Laboratoires Urgo Fluid composition containing a sun filter, and use thereof for the treatment of scars
US20130142881A1 (en) * 2011-12-02 2013-06-06 The Mothervine Nutraceutical Co. Llc Lip Balm Composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3258942A4 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2554966A (en) * 2016-05-23 2018-04-18 Henkel Ag & Co Kgaa Deodorizing combination of active ingredients
GB2554966B (en) * 2016-05-23 2019-04-10 Henkel Ag & Co Kgaa Deodorizing combination of active ingredients
US11980592B2 (en) 2016-10-11 2024-05-14 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
US10857107B2 (en) 2017-02-01 2020-12-08 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
CN107789255A (zh) * 2017-11-30 2018-03-13 安徽扬子生物科技有限公司 一种茉莉花抗菌沐浴露配制方法
KR20210008327A (ko) * 2018-01-13 2021-01-21 트루티바 인코포레이티드 노화 방지 및 피부 톤 미백 조성물 및 이를 위한 방법
WO2019140357A1 (fr) * 2018-01-13 2019-07-18 Truetiva Inc. Compositions anti-âge et d'éclaircissement du teint de la peau et méthodes associées
KR102632946B1 (ko) * 2018-01-13 2024-02-05 트루티바 인코포레이티드 노화 방지 및 피부 톤 미백 조성물 및 이를 위한 방법
WO2019144189A1 (fr) * 2018-01-24 2019-08-01 Botanix Pharmaceuticals Ltd Régime de dosage de cannabinoïde pour l'acné
EP3743056A4 (fr) * 2018-01-24 2022-08-10 Botanix Pharmaceuticals Ltd Régime de dosage de cannabinoïde pour l'acné
AU2019211468B2 (en) * 2018-01-24 2024-05-02 Botanix Pharmaceuticals Ltd Cannabinoid dosing regime for acne
WO2020000024A1 (fr) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Traitement antibactérien utilisant des combinaisons de cannabinoïdes
WO2020252522A1 (fr) * 2019-06-18 2020-12-24 Botanix Pharmaceuticals Limited Régime posologique antibactérien utilisant des cannabinoïdes
WO2021092340A1 (fr) * 2019-11-07 2021-05-14 Amyris, Inc. Compositions et procédés d'administration de cannabinoïdes à la peau
US11213467B2 (en) 2019-11-07 2022-01-04 Amyris, Inc. Compositions and methods for delivering cannabinoids to skin
US11219586B2 (en) 2019-11-07 2022-01-11 Amyris, Inc. Compositions and methods for delivering cannabinoids to skin
WO2021116808A1 (fr) * 2019-12-10 2021-06-17 Avicanna Inc. Composition topique de soin de la peau et méthodes de traitement de l'eczéma
WO2022150761A1 (fr) * 2021-01-11 2022-07-14 Amyris, Inc. Compositions cosmétiques et ses procédés d'utilisation
WO2023012803A1 (fr) * 2021-08-05 2023-02-09 Technion Research & Development Foundation Limited Cannabinoïdes et leurs utilisations dans le traitement d'une maladie
EP4268799A1 (fr) * 2022-04-01 2023-11-01 TF Holdings LLC Composition de traitement de la peau contenant des cannabinoïdes

Also Published As

Publication number Publication date
EP3258942A1 (fr) 2017-12-27
US20160235661A1 (en) 2016-08-18
EP3258942A4 (fr) 2018-11-14
ES2860452T3 (es) 2021-10-05
DK3258942T3 (da) 2021-01-25
US20200188325A1 (en) 2020-06-18
EP3258942B1 (fr) 2021-01-13
HK1248526A1 (zh) 2018-10-19

Similar Documents

Publication Publication Date Title
EP3258942B1 (fr) Compositions cosmétiques et topiques comprenant du cannabigérol et du cannabidiol
Pundir et al. Ethnomedicinal uses, phytochemistry and dermatological effects of Hippophae rhamnoides L.: A review
US20190209631A1 (en) Lipid Extract of Passiflora Seeds
KR20190128666A (ko) 미용 스킨케어 조성물들의 키트
JP7275103B2 (ja) ネフェリウム・ラパセウム（Ｎｅｐｈｅｌｉｕｍ ｌａｐｐａｃｅｕｍ）抽出物の新規な美容的使用
KR20050071464A (ko) 펩타이드 구리 착체 및 식물화학적 화합물을 함유하는조성물 및 이와 관련된 방법
CA2895218A1 (fr) Extrait de graines de passiflore et compositions cosmetiques, pharmaceutiques, dermatologiques ou nutraceutiques le comprenant
US11484559B2 (en) Kapok tree flower extract, and cosmetic, pharmaceutical or dermatological compositions containing same
KR102142311B1 (ko) 텐저레틴을 함유하는 피부 외용제 조성물
Pinto et al. Cosmetics—Food waste recovery
EP2691074A1 (fr) Composition a base de camellia japonica et polygonum hydropiper pour protection de la peau
CN110072516B (zh) 包含作为有效成分的中药材提取物的化妆料组合物
KR20160120355A (ko) 피부-윤광 화장품 조성물
KR20190128665A (ko) 미용 스킨케어 조성물
EP2100593B1 (fr) Mélanges ternaires dotés d'un effet croissant de synthèse du collagène
KR101744889B1 (ko) 항산화, 미백 및 주름개선 효과를 갖는 조성물
TWI523666B (zh) 包含歐洲百合萃取物之組成物及其用途（二）
WO2012014901A1 (fr) Inhibiteur de carbonylation
KR20120068707A (ko) 마르타곤 나리 추출물을 포함하는 조성물 및 이의 용도
KR101304677B1 (ko) 밤송이 추출물 및 이를 유효성분으로 함유하는 화장료 조성물
KR102525579B1 (ko) 쌀, 갈대, 옥촉서예, 당아욱 및 알로에추출물을 포함하는 피부 보호용 화장료 조성물
KR20170137559A (ko) 복합 생약 추출물을 포함하는 피부 개선용 조성물
Jain et al. A Review on Herbal Cosmetics and Cosmeceuticals
Parhi The role of phytocompounds in cosmeceutical applications
KR102397926B1 (ko) 피부 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16752852

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2016752852

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE